Bayer CropScience and FuturaGene sign license agreement for drought tolerance technology in cotton
Bayer CropScience and FuturaGene PLC have entered into a license agreement for a drought tolerance technology. The agreement grants Bayer CropScience exclusive worldwide rights to utilize a FuturaGene drought tolerance technology in cotton. FuturaGene will receive an upfront license fee, followed by development milestone payments and trait royalties on sales of cotton seeds incorporating this technology. Further financial details were not disclosed.
The technology licensed to Bayer is intended to protect the yield of cotton plants when they are subjected to drought. Drought is one of the principal environmental limits of crop yield as it hampers the cultivation of crops on more than 40 percent of the earth’s land surface, posing a serious threat to global agricultural production and food supplies.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Crucell HIV Vaccine: Promising Preliminary Results Phase I Study

No particular risk of infection of Sars-Cov-2 by cash - For fear of contagion, the pandemic is much more cashless payments
Human antibodies produced in DNA-vaccinated cows protect in lethal models of hantavirus
Polycystic_kidney_disease
ATLAS Biolabs participates in two European research projects to investigate DNA repair and cellular aging
Hantavirus
Cellexus Biosystems reports the Granting of Fundamental Technology UK Patent
Innovacell Includes First Patients in a Phase IIb Study for Its Cell Therapy Product urocell
